DUPIXENT (dupilumab) injection

DUPIXENT is a prescription medicine used for the treatment of Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis. Brand Name: DUPIXENT (dupilumab) injection, for subcutaneous use Initial U.S. Approval: 2017. FDA approved dupilumab (brand name DUPIXENT) is not (yet) registered or available in India but on request Indian patient can buy DUPIXENT at the lowest price.

DUPIXENT (dupilumab) injection Price In India and Overseas
DUPIXENT (dupilumab) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

DUPIXENT (dupilumab) injection

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.

DUPIXENT is an interleukin-4 receptor alpha antagonist indicated:

Atopic Dermatitis
for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical
prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma
as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Chronic Rhinosinusitis with Nasal Polyposis
as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Eosinophilic Esophagitis
for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE). (1.4)

Prurigo Nodularis
for the treatment of adult patients with prurigo nodularis (PN).

Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP).

In May 2022, the indication for dupilumab was updated to include the treatment of eosinophilic esophagitis in people aged twelve years of age and older weighing at least 40 kilograms (88 lb).

In September 2022, the indication for dupilumab was updated to include the treatment of adults with prurigo nodularis (PN).

In March 2023, the EMA approved dupilumab for the treatment of severe atopic dermatitis in children aged six months to five years who are candidates for systemic therapy.

Drug (Brand / Generic): DUPIXENT / dupilumab
Current Indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis
Marketed by:: Regeneron
Approval Date: 2017

Dosage forms and strengths of DUPIXENT (dupilumab) injection
Single-Dose Pre-Filled Syringe with Needle Shield:
• Injection: 300 mg/2 mL
• Injection: 200 mg/1.14 mL
• Injection: 100 mg/0.67 mL
Single-Dose Pre-Filled Pen:
• Injection: 300 mg/2 mL
• Injection: 200 mg/1.14 mL

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.